Skip to main content
. 2008 Dec 10;26(35):5748–5754. doi: 10.1200/JCO.2008.17.5448

Table 2.

Treatment Characteristics: Percentage of Patients per Cycle Who Received Full Therapy

Characteristic % of Patients per Cycle Who Received Full Therapy
CVD Arm BCT Arm
Cycle 1 n = 187 n = 177
    Cisplatin 99 93
    Vinblastine 98 95
    Dacarbazine 99 98
    IL-2 87
    IFN 60
Cycle 2 n = 159 n = 154
    Cisplatin 97 84
    Vinblastine 93 82
    Dacarbazine 94 84
    IL-2 73
    IFN 57
Cycle 3 n = 93 n = 96
    Cisplatin 97 80
    Vinblastine 92 71
    Dacarbazine 91 74
    IL-2 67
    IFN 40
Cycle 4 n = 81 n = 82
    Cisplatin 94 72
    Vinblastine 80 59
    Dacarbazine 81 60
    IL-2 57
    IFN 37

Abbreviations: CVD, cisplatin, vinblastine, and dacarbazine; BCT, biochemotherapy; IL-2, interleukin-2; IFN, interferon alfa-2b.